Bcr/abl+ autologous dendritic cells for vaccination in chronic myeloid leukemia

Tools

Item Type:	Article
Title:	Bcr/abl+ autologous dendritic cells for vaccination in chronic myeloid leukemia
Creators Name:	Westermann, J., Kopp, J., Koerner, I., Richter, G., Qin, Z., Blankenstein, T., Doerken, B. and Pezzutto, A.
Abstract:	In chronic myeloid leukemia (CML) ex vivo generated DC are characterized by constitutive expression of bcr/abl and possibly other yet undefined leukemia-associated antigens, since these DC share a common progeny with leukemic cells. Induction of anti-leukemic T cell responses has been described in vitro. For a phase I vaccination study, autologous bcr/abl+ DC are generated under GMP conditions mainly from monocyte precursors in chronic phase CML patients. Lin-, CD80+, CD86+, CD83+, DR+ DC could be generated in sufficient numbers for s.c. vaccination with 1 × 106-5 × 107 DC. Using monocyte precursors, the yield of DC per seeded PBMC was in the range of 1-6%. Furthermore, we could demonstrate in vitro that the T cell stimulatory ability of CD34+-derived DC can be augmented by a factor 2-3 by retroviral transduction with a gene coding for interleukin-7. DC-based vaccination strategies are a promising clinical approach, particularly as postremission immunotherapy in the setting of autologous stem cell transplantation.
Keywords:	CML, Dendritic Cells, Interleukin-7, Vaccination
Source:	Bone Marrow Transplantation
ISSN:	0268-3369
Publisher:	Nature Publishing Group
Volume:	25 Suppl. 2
Number:	3332
Page Range:	S46-S49
Date:	1 May 2000
Official Publication:	http://www.nature.com/bmt/journal/v25/n2s/abs/1702354a.html
PubMed:	View item in PubMed

Repository Staff Only: item control page